106 related articles for article (PubMed ID: 30655870)
1. HNF1B expression regulates ECI2 gene expression, potentially serving a role in prostate cancer progression.
Dan C; Zhang H; Zeng W; Huang L; Gong X; Li H; Yang E; Wang L; Yao Q
Oncol Lett; 2019 Jan; 17(1):1094-1100. PubMed ID: 30655870
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122 cases of high-grade serous ovarian carcinoma.
Němejcová K; Bártů M; Hojný J; Hájková N; Michálková R; Krkavcová E; Stružinská I; Bui HQ; Dundr P; Cibula D; Jirsová K
Oncol Lett; 2021 Mar; 21(3):185. PubMed ID: 33574924
[TBL] [Abstract][Full Text] [Related]
3. HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study.
Dundr P; Bártů M; Hojný J; Michálková R; Hájková N; Stružinská I; Krkavcová E; Hadravský L; Kleissnerová L; Kopejsková J; Hiep BQ; Němejcová K; Jakša R; Čapoun O; Řezáč J; Jirsová K; Franková V
Sci Rep; 2020 Sep; 10(1):14365. PubMed ID: 32873863
[TBL] [Abstract][Full Text] [Related]
4. Lipid degradation promotes prostate cancer cell survival.
Itkonen HM; Brown M; Urbanucci A; Tredwell G; Ho Lau C; Barfeld S; Hart C; Guldvik IJ; Takhar M; Heemers HV; Erho N; Bloch K; Davicioni E; Derua R; Waelkens E; Mohler JL; Clarke N; Swinnen JV; Keun HC; Rekvig OP; Mills IG
Oncotarget; 2017 Jun; 8(24):38264-38275. PubMed ID: 28415728
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
[TBL] [Abstract][Full Text] [Related]
6. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
[TBL] [Abstract][Full Text] [Related]
7. HNF1b is involved in prostate cancer risk via modulating androgenic hormone effects and coordination with other genes.
Hu YL; Zhong D; Pang F; Ning QY; Zhang YY; Li G; Wu JZ; Mo ZN
Genet Mol Res; 2013 Apr; 12(2):1327-35. PubMed ID: 23661456
[TBL] [Abstract][Full Text] [Related]
8. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
Chung AC; Zhou S; Liao L; Tien JC; Greenberg NM; Xu J
Cancer Res; 2007 Jun; 67(12):5965-75. PubMed ID: 17575167
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
10. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
11. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
13. A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice.
Farina NH; Zingiryan A; Akech JA; Callahan CJ; Lu H; Stein JL; Languino LR; Stein GS; Lian JB
Oncotarget; 2016 Oct; 7(43):70462-70474. PubMed ID: 27634876
[TBL] [Abstract][Full Text] [Related]
14. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
[TBL] [Abstract][Full Text] [Related]
15. Hexim-1 modulates androgen receptor and the TGF-β signaling during the progression of prostate cancer.
Mascareno EJ; Belashov I; Siddiqui MA; Liu F; Dhar-Mascareno M
Prostate; 2012 Jun; 72(9):1035-44. PubMed ID: 22095517
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
Shukla S; Maclennan GT; Marengo SR; Resnick MI; Gupta S
Prostate; 2005 Aug; 64(3):224-39. PubMed ID: 15712212
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
[TBL] [Abstract][Full Text] [Related]
18. P21 and P27 promote tumorigenesis and progression via cell cycle acceleration in seminal vesicles of TRAMP mice.
Li T; Wang F; Dang Y; Dong J; Zhang Y; Zhang C; Liu P; Gao Y; Wang X; Yang S; Lu S
Int J Biol Sci; 2019; 15(10):2198-2210. PubMed ID: 31592235
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
20. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
